Isolation, cultivation, and characterization of primary bovine cochlear pericytes: A new in vitro model of stria vascularis.
Actins
/ metabolism
Animals
Antigens
/ metabolism
Biomarkers
/ metabolism
Cattle
Cell Culture Techniques
/ methods
Cell Survival
Cisplatin
/ toxicity
Cochlea
/ cytology
Culture Media
Drug Evaluation, Preclinical
/ methods
Gentamicins
/ toxicity
In Vitro Techniques
Models, Biological
Ototoxicity
/ etiology
Pericytes
/ cytology
Proteoglycans
/ metabolism
Receptor, Platelet-Derived Growth Factor beta
/ metabolism
Stria Vascularis
/ cytology
cisplatin
gentamicin
ototoxicity
pericytes
primary culture
stria vascularis
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
04
06
2018
accepted:
14
09
2018
pubmed:
15
10
2018
medline:
3
1
2020
entrez:
15
10
2018
Statut:
ppublish
Résumé
The study of strial pericytes has gained great interest as they are pivotal for the physiology of stria vascularis. To provide an easily accessible in vitro model, here we described a growth medium-based approach to obtain and cultivate primary bovine cochlear pericytes (BCP) from the stria vascularis of explanted bovine cochleae. We obtained high-quality pericytes in 8-10 days with a > 90% purity after the second passage. Immunocytochemical analysis showed a homogeneous population of cells expressing typical pericyte markers, such as neural/glial antigen 2 (NG2), platelet-derived growth factor receptorβ (PDGFRβ), α-smooth muscle actin (α-SMA), and negative for the endothelial marker von Willebrand factor. When challenged with tumor necrosis factor or lipopolysaccharide, BCP changed their shape, similarly to human retinal pericytes (HRPC). The sensitivity of BCP to ototoxic drugs was evaluated by challenging with cisplatin or gentamicin for 48 hr. Compared to human retinal endothelial cells and HRPC, cell viability of BCP was significantly lower ( p < 0.05) after the treatment with gentamicin or cisplatin. These data indicate that our protocol provides a simple and reliable method to obtain highly pure strial BCP. Furthermore, BCP are suitable to assess the safety profile of molecules which supposedly exert ototoxic activity, and may represent a valid alternative to in vivo tests.
Substances chimiques
Actins
0
Antigens
0
Biomarkers
0
Culture Media
0
Gentamicins
0
Proteoglycans
0
chondroitin sulfate proteoglycan 4
0
Receptor, Platelet-Derived Growth Factor beta
EC 2.7.10.1
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1978-1986Informations de copyright
© 2018 Wiley Periodicals, Inc.